Auriemma CL, Zhuo H, Delucchi K, et al. Acute respiratory distress syndrome-attributable mortality in critically ill patients with sepsis. Intensive Care Med. Published online March 23, 2020. doi:10.1007/s00134-020-06010-9
Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788-800. doi:10.1001/jama.2016.0291
Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides. 2000;21(2):265-269. doi:10.1016/s0196-9781(99)00202-8
Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162(2):1200-1205.
Feliciano L, Henning RJ. Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow. Cardiovasc Res. 1998;40(1):45-55. doi:10.1016/s0008-6363(98)00122-9
Fraccaroli L, Grasso E, Hauk V, et al. Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental–maternal leucocyte interaction impair the maternal tolerogenic response. Clin Exp Immunol. 2012;170(3):310-320. doi:10.1111/j.1365-2249.2012.04668.x
Frase LL, Gaffney FA, Lane LD, et al. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol. 1987;60(16):1356-1361. doi:10.1016/0002-9149(87)90619-9
Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf). 2015;213(2):442-452. doi:10.1111/apha.12427
Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol. 1996;71(1-2):25-30. doi:10.1016/s0165-5728(96)00118-x
Kane MG, O’Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med. 1983;309(24):1482-1485. doi:10.1056/NEJM198312153092403
Ke L-Q, Wang F-M, Luo Y-C. [Effects of vasoactive intestinal peptide on airway inflammation and Th17/Treg balance in asthmatic mice]. Zhongguo Dang Dai Er Ke Za Zhi. 2017;19(6):699-704.
Krejs GJ, Fordtran JS, Fahrenkrug J, et al. Effect of VIP infusion in water and ion transport in the human jejunum. Gastroenterology. 1980;78(4):722-727.
Li L, Luo ZQ, Zhou M, et. al. Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants. Acta Pharmacol Sin 2004;25:1652-1658.
Martínez C, Delgado M, Pozo D, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998;63(5):591-601. doi:10.1002/jlb.63.5.591
Murray JF, Matthay MA, Luce JM & Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Resp Dis 1988;138: 720-723.
Nicholas TE: Pulmonary surfactant: no mere paint on the alveolar wall. Respirology 1996, 1:247–257.
Onoue S, Ohmori Y, Endo K, Yamada S, Kimura R, Yajima T. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur J Biochem. 2004;271(9):1757-1767. doi:10.1111/j.1432-1033.2004.04086.x
Power RF, Bishop AE, Wharton J, et al. Anatomical distribution of vasoactive intestinal peptide binding sites in peripheral tissues investigated by in vitro autoradiography. Ann N Y Acad Sci. 1988;527:314-325. doi:10.1111/j.1749-6632.1988.tb26989.x
Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540-548. doi:10.1164/rccm.200909-1451OC
Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 1970; 225: 863-864.
Ran W-Z, Dong L, Tang C-Y, et al. Vasoactive intestinal peptide suppresses macrophage-mediated inflammation by downregulating interleukin-17A expression via PKA- and PKC-dependent pathways. Int J Exp Pathol. 2015;96(4):269-275. doi:10.1111/iep.12130
Smitherman TC, Popma JJ, Said SI, Krejs GJ, Dehmer GJ. Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans. American Journal of Physiology-Heart and Circulatory Physiology. 1989;257(4):H1254-H1262. doi:10.1152/ajpheart.1989.257.4.H1254